Premier Alternatives

Third Pole Therapeutics

Waltham, MA · Founded 2014 · Privately Held (backing)

Developer of a medical inhalation device designed to offer life-saving cardiopulmonary therapies. Third Pole Therapeutics is based in Waltham, MA and was founded in 2014. Its last reported valuation was $240 million in Mar 2025. It has raised $126 million.

Last reported valuation
$240.0M
Oct 2026
Priced at
—
Total raised
$125.8M
Last round
—

Third Pole Therapeutics key facts

as of Oct 2026
  • Developer of a medical inhalation device designed to offer life-saving cardiopulmonary therapies.
  • Third Pole Therapeutics is valued at approximately $240.0M as of Oct 2026 (last reported valuation).
  • It has raised $125.8M; the latest was Later Stage VC ($16.9M) in Mar 2025.
  • Notable investors include National Institutes of Health, Johnson & Johnson Innovation - JLABS, Acorn Campus Taiwan, Lung, Michael Marsh — 11 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$240.0M

Third Pole Therapeutics's last reported valuation, Mar 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Third Pole Therapeutics with a free account
  • ·The complete investor list: 11 names
  • ·Watch Third Pole Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Third Pole Therapeutics funding rounds

No rounds on record

No funding rounds for Third Pole Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Third Pole Therapeutics valuation

Third Pole Therapeutics's last reported valuation was $240 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.

Third Pole Therapeutics investors

11 investors are on record for Third Pole Therapeutics, including National Institutes of Health, Johnson & Johnson Innovation - JLABS, Acorn Campus Taiwan and Lung.

About Third Pole Therapeutics

Developer of a medical inhalation device designed to offer life-saving cardiopulmonary therapies. The company's device serves as the current standard of care to treat hypoxic respiratory failure in newborns, as it is capable of generating nitric oxide from air and electricity on-demand and on-site which potentially eliminates the need for large compressed gas cylinders, enabling clinicians to acquire flexible and innovative options in therapeutic fields beyond hypoxic respiratory failure, including pulmonary hypertension, interstitial lung disease, and chronic obstructive pulmonary disease.

Sector
Healthcare
HQ
Waltham, MA, United States
Founded
2014
Employees
31
Website
pole3.com/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.